Skip to main content

Table 2 Treatment outcomes after NAC/IDS

From: Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708)

Characteristics N (%)
NAC response
 CA-125, n (%)
  CA-125 after 3rd NAC < 35 49 (31.8)
  CA-125 reduction rate ≥ 90% 61 (39.6)
 Response rate after 3rd NAC, n (%)
  CR 2 (1.3)
  PR 98 (63.6)
  SD 21 (13.6)
  PD 7 (4.5)
  Unknown 26 (16.9)
Surgical outcome
 Surgery extent, n (%)
  Standard 82 (53.3)
  Radical 69 (44.8)
  Not surgery 3 (1.9)
 Residual disease after IDS, n (%)
  ≤1 cm 103 (66.9)
  >1 cm 25 (16.2)
  Unknown 26 (16.9)
 Lymphadenectomy, n (%)
  (−) 36 (23.4)
  (+) 115 (74.7)
  Unknown 3 (1.9)
 Lymph node metastasis, n (%)
  No 88 (57.2)
  Yes 63 (40.9)
  Unknown 3 (1.9)
 Peritoneal cytology, n (%)
  Negative 57 (37.0)
  Positive 63 (40.9)
 Not tested 27 (17.5)
  Unknown 7 (4.6)
 Postoperative complications*
  0–2 143 (92.9)
  3–5 8 (5.2)
  Unknown 3 (1.9)
  1. NAC neoadjuvant chemotherapy, IDS interval debulking surgery, HGSC high-grade serous carcinoma, CA 125 cancer antigen 125, CR complete response, PR partial response, SD stable disease, PD progressive disease
  2. *According to the Memorial Sloan-Kettering Cancer Center’s surgical secondary events grading system
\